USE OF GENETIC MARKERS FOR IDENTIFYING THE RESPONSE TO INTERFERON TREATMENT IN MULTIPLE SCLEROSIS PATIENTS

摘要

The present invention relates to the use of genetic markers to identify the response to interferon-beta (IFN-beta) treatment in Multiple Sclerosis (MS) patients as well as a method for treating MS patients and kits for genotyping.